Literature DB >> 15935549

Allopregnanolone and pregnanolone are produced by the human corpus luteum.

Ulrika Ottander1, Inger Sundström Poromaa, Erik Bjurulf, Asa Skytt, Torbjörn Bäckström, Jan I Olofsson.   

Abstract

Using a dispersed human luteal cell culture model, progesterone, allopregnanolone and pregnanolone release following treatment by incremental doses of human chorionic gonadotrophin (hCG) were evaluated. Corpus luteum tissues, obtained from 48 healthy women scheduled for benign surgery, were grouped according to luteal age and tissue concentration of allopregnanolone and pregnanolone was determined. The mRNA expression of 5alpha-, and 5beta-reductase and 3alpha-HSOR mRNA expressions were evaluated in corpora lutea from the late luteal phase. Allopregnanolone concentrations in corpus luteum tissue were consistently about three- to four-fold higher than pregnanolone levels. Allopregnanolone tissue concentrations significantly decreased between early- and late-luteal phase, p<0.05. When exposed to hCG, progesterone output from freshly obtained human corpora lutea cells was two- three-fold increased compared to control levels. With 0.1U/ml hCG a two-fold increase in allopregnanolone levels were noted, whereas pregnanolone levels were increased by approximately 40%. Furthermore, the mRNA of 5alpha-, 5beta-reductase and 3alpha-HSOR mRNA were all expressed in human corpus luteum. In conclusion, the neurosteroids allopregnanolone and pregnanolone are produced in the human corpus luteum and their release is stimulated by trophic hormone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15935549     DOI: 10.1016/j.mce.2005.04.007

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  19 in total

Review 1.  Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders.

Authors:  Anna-Carin N-Wihlbäck; Inger Sundström-Poromaa; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2005-12-15       Impact factor: 4.530

2.  Sex differences in neurosteroid and hormonal responses to metyrapone in posttraumatic stress disorder.

Authors:  Sabra S Inslicht; Anne Richards; Erin Madden; Madhu N Rao; Aoife O'Donovan; Lisa S Talbot; Evelyn Rucker; Thomas J Metzler; Richard L Hauger; Thomas C Neylan
Journal:  Psychopharmacology (Berl)       Date:  2014-06-21       Impact factor: 4.530

Review 3.  The role of ovarian hormone-derived neurosteroids on the regulation of GABAA receptors in affective disorders.

Authors:  Georgina MacKenzie; Jamie Maguire
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

Review 4.  GABAA Receptor-Modulating Steroids in Relation to Women's Behavioral Health.

Authors:  Torbjörn Bäckström; Marie Bixo; Jessica Strömberg
Journal:  Curr Psychiatry Rep       Date:  2015-11       Impact factor: 5.285

5.  Pharmacokinetic and behavioral effects of allopregnanolone in healthy women.

Authors:  Erika Timby; Matts Balgård; Sigrid Nyberg; Olav Spigset; Agneta Andersson; Joanna Porankiewicz-Asplund; Robert H Purdy; Di Zhu; Torbjörn Bäckström; Inger Sundström Poromaa
Journal:  Psychopharmacology (Berl)       Date:  2005-09-21       Impact factor: 4.530

6.  Thalamic Gamma Aminobutyric Acid Level Changes in Major Depressive Disorder After a 12-Week Iyengar Yoga and Coherent Breathing Intervention.

Authors:  Chris C Streeter; Patricia L Gerbarg; Richard P Brown; Tammy M Scott; Greylin H Nielsen; Liz Owen; Osamu Sakai; Jennifer T Sneider; Maren B Nyer; Marisa M Silveri
Journal:  J Altern Complement Med       Date:  2020-01-14       Impact factor: 2.579

Review 7.  Tolerance to allopregnanolone with focus on the GABA-A receptor.

Authors:  Sahruh Turkmen; Torbjorn Backstrom; Goran Wahlstrom; Lotta Andreen; Inga-Maj Johansson
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

8.  Exogenous progesterone for smoking cessation in men and women: a pilot double-blind, placebo-controlled randomized clinical trial.

Authors:  Nicole L Tosun; Ann M Fieberg; Lynn E Eberly; Katherine A Harrison; Angela R Tipp; Alicia M Allen; Sharon S Allen
Journal:  Addiction       Date:  2019-06-17       Impact factor: 6.526

9.  Studies of pharmacokinetic and pharmacodynamic properties of isoallopregnanolone in healthy women.

Authors:  Helena Hedström; Marie Bixo; Sigrid Nyberg; Olav Spigset; Elisabeth Zingmark; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2008-10-24       Impact factor: 4.530

10.  The allopregnanolone to progesterone ratio across the menstrual cycle and in menopause.

Authors:  Allison Kimball; Laura E Dichtel; Maren B Nyer; David Mischoulon; Lauren B Fisher; Cristina Cusin; Christina M Dording; Nhi-Ha Trinh; Albert Yeung; Melanie S Haines; Joshua C Sung; Graziano Pinna; Ann M Rasmusson; Linda L Carpenter; Maurizio Fava; Anne Klibanski; Karen Klahr Miller
Journal:  Psychoneuroendocrinology       Date:  2019-11-14       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.